Syndax Pharmaceuticals Inc — Director's Dealing 2021

Dec 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-12-13

Reporting Person: Metzger Michael A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-13	Common Stock	M	2045.00	$7.20	Acquired	19704.00	Direct
2021-12-13	Common Stock	S	2045.00	$19.0532	Disposed	17659.00	Direct
2021-12-13	Common Stock	M	34564.00	$6.38	Acquired	52223.00	Direct
2021-12-13	Common Stock	S	34564.00	$19.0532	Disposed	17659.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-13	Stock Options (Right to buy)	$7.20	M	2045.00	Disposed	2025-06-01	Common Stock (2045.00)	Direct
2021-12-13	Stock Options (Right to buy)	$6.38	M	34564.00	Disposed	2029-02-06	Common Stock (34564.00)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 681,422 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested.

F2: The sale prices ranged from $19.00 to $19.49.

F3: This option is fully vested.